Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CBER’s New Director 'Marks' New Era For Biologics Regulation

This article was originally published in The Pink Sheet Daily

Executive Summary

Peter Marks takes over top spot in FDA's center for biologics after four-year training period as deputy director; his background appears well suited to what promises to be a transformative era in medicine.

You may also be interested in...

CBER Reorganization Groups Hematology Products With Cell Therapies

Director Peter Marks makes his mark in shuffling of office divisions aimed at regulatory efficiency.

FDA Talent Hunt: Is Recruiting From Academia Better Than Industry?

CDER Oncology office head Richard Pazdur says making FDA more academic could help with retention.

The Rebate Rule May Not Last, But It Changed The Pricing Debate

Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts